Investigating the Role of Autologous Conditioned Serum in Triangular Fibrocartilage Complex Injuries
DOI:
https://doi.org/10.9734/bpi/cpms/v6/2397AKeywords:
Autologous, triangular fibrocartilage, radio-ulnar joint (DRUJ)Abstract
Aim: To Evaluate Functional & Clinical Results of ACS in TFCC Injuries.
Materials and Methods: A) A Study of 28 Cases Done between September 2019 to December 2021.
- B) 28 patients with Clinical and Radiological Evidence of TFCC Injuries Secondary to Sporting Activities Were Recruited for This Study.
- C) Diagnosis is made clinically, plain radiographs, ultrasound & MRI
Results: 26 Cases Came for Complete Followup.2 Cases Lost Follow-Up After Injection.16 Cases Had Excellent Results, 06 Cases Had Good Results and 04 Had Poor Result At The End Of 6 Weeks. But At The End Of 03 Months, Follow Up With 22 Cases (16+06) Gave us a Total Positive Response And We Labelled Them Under The Excellent Result Category.
04 Cases Who Had Poor Results at the End Of 6 Weeks Were Given One More Shot Of ACS &They Gave Good Response at the End Of 6 Weeks After 2nd ACS Injection.
Conclusion: Through ACS Therapy, We Have Found that Pain Can Be Dramatically Reduced And Healing Stimulated. Treatment Is Fast-Acting While Providing Long-Lasting Relief. Time to Return To Sporting and Gym Activities Also Reduced Compared to Conventional Treatment in Which It Is 3 Months, Where as in this Study We Found Time took to Getting Back to Gym & Sports-Related Activities Is 6weeks. We Are in the Opinion That ACS is a Safe Method to Treat Type 1 TFCC Injuries in Terms of Faster Returning to activities and also in Getting Rid of Pain Along With No Complications.
